During the last session, Myriad Genetics, Inc (NASDAQ:MYGN)’s traded shares were 1.66 million, with the beta value of the company hitting 1.87. At the end of the trading day, the stock’s price was $4.16, reflecting an intraday loss of -3.93% or -$0.17. The 52-week high for the MYGN share is $29.30, that puts it down -604.33 from that peak though still a striking 8.41% gain since the share price plummeted to a 52-week low of $3.81. The company’s market capitalization is $383.46M, and the average intraday trading volume over the past 10 days was 2.17 million shares, and the average trade volume was 1.95 million shares over the past three months.
Myriad Genetics, Inc (MYGN) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 3.00. MYGN has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Myriad Genetics, Inc (NASDAQ:MYGN) trade information
Myriad Genetics, Inc (MYGN) registered a -3.93% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.93% in intraday trading to $4.16, hitting a weekly high. The stock’s 5-day price performance is 2.21%, and it has moved by -42.22% in 30 days. Based on these gigs, the overall price performance for the year is -82.04%. The short interest in Myriad Genetics, Inc (NASDAQ:MYGN) is 7.92 million shares and it means that shorts have 2.47 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.5, which implies an increase of 66.72% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $21 respectively. As a result, MYGN is trading at a discount of -404.81% off the target high and -44.23% off the low.
MYGN Dividends
Myriad Genetics, Inc is due to release its next quarterly earnings on 2025-May-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Myriad Genetics, Inc (NASDAQ:MYGN)’s Major holders
Myriad Genetics, Inc insiders own 2.36% of total outstanding shares while institutional holders control 104.31%, with the float percentage being 106.83%. BLACKROCK INC. is the largest shareholder of the company, while 326.0 institutions own stock in it. As of 2024-06-30, the company held over 15.15 million shares (or 16.7227% of all shares), a total value of $370.59 million in shares.
The next largest institutional holding, with 10.06 million shares, is of VANGUARD GROUP INC’s that is approximately 11.1089% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $246.18 million.
Also, the Mutual Funds coming in first place with the largest holdings of Myriad Genetics, Inc (MYGN) shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD EXPLORER FUND. Data provided on Apr 30, 2025 indicates that iShares Trust-iShares Core S&P Small-Cap ETF owns about 5.5 shares. This amounts to just over 5.97 percent of the company’s overall shares, with a $22.9 million market value. The same data shows that the other fund manager holds slightly less at 3.29, or about 3.57% of the stock, which is worth about $13.7 million.
